Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

All appraisals

1,189 appraisals, newest first, page 2 of 12
AppraisalMedicine pageNICE recommendationPublishedStatus
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal)
NICE TA1089
Sacituzumab GovitecanTerminated (no company submission)13 Aug 2025Current
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over
NICE TA1088
RuxolitinibNot recommended13 Aug 2025Current
12 SQ-Bet SLIT for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen in people 5 years and over
NICE TA1087
—Recommended6 Aug 2025
Updated 26 Aug 2026
Current
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence
NICE TA1086
RibociclibRecommended6 Aug 2025Current
Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over
NICE TA1085
Tezacaftor, DeutivacaftorOptimised30 Jul 2025
Updated 30 Jul 2025
Current
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)
NICE TA1084
Idecabtagene vicleucelTerminated (no company submission)23 Jul 2025Current
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal)
NICE TA1083
Lisocabtagene maraleucelTerminated (no company submission)23 Jul 2025Current
Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal)
NICE TA1082
LetermovirTerminated (no company submission)23 Jul 2025Current
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma
NICE TA1081
ZanubrutinibOptimised10 Jul 2025Current
Mirikizumab for previously treated moderately to severely active Crohn's disease
NICE TA1080
MirikizumabOptimised10 Jul 2025Current
Fruquintinib for previously treated metastatic colorectal cancer
NICE TA1079
FruquintinibOptimised23 Jul 2025Current
Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal)
NICE TA1078
—Terminated (no company submission)25 Jun 2025Current
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over
NICE TA1077
NemolizumabOptimised2 Jul 2025Current
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)
NICE TA1076
AdagrasibTerminated (no company submission)2 Jul 2025Current
Dapagliflozin for treating chronic kidney disease
NICE TA1075
DapagliflozinOptimised2 Jul 2025Current
Sparsentan for treating primary IgA nephropathy
NICE TA1074
SparsentanOptimised25 Jun 2025
Updated 9 Oct 2025
Current
Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies
NICE TA1073
MarstacimabOptimised24 Jun 2025Current
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
NICE TA1072
TislelizumabTerminated (no company submission)19 Jun 2025Current
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
NICE TA1071
AtezolizumabRecommended19 Jun 2025Current
Spesolimab for treating generalised pustular psoriasis flares
NICE TA1070
SpesolimabOptimised18 Jun 2025Current
Efgartigimod for treating antibody-positive generalised myasthenia gravis
NICE TA1069
EfgartigimodNot recommended4 Jun 2025Current
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal)
NICE TA1068
TislelizumabTerminated (no company submission)29 May 2025Current
Linzagolix for treating symptoms of endometriosis
NICE TA1067
—Recommended4 Jun 2025Current
Somapacitan for treating growth hormone deficiency in people 3 to 17 years
NICE TA1066
SomapacitanRecommended3 Jun 2025Current
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
NICE TA1065
NivolumabRecommended28 May 2025Current
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
NICE TA1064
DostarlimabOptimised22 May 2025Current
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment
NICE TA1063
CapivasertibOptimised15 May 2025Current
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor
NICE TA1062
ErdafitinibRecommended12 May 2025Current
Omaveloxolone for treating Friedreich’s ataxia in people 16 years and over (terminated appraisal)
NICE TA1061
OmaveloxoloneTerminated (no company submission)6 May 2025Current
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer
NICE TA1060
OsimertinibRecommended8 May 2025Current
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma
NICE TA1059
Brentuximab VedotinRecommended7 May 2025Current
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)
NICE TA1058
TislelizumabTerminated (no company submission)23 Apr 2025Current
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis
NICE TA1057
Relugolix, EstradiolRecommended16 Apr 2025Current
Molnupiravir for treating COVID-19
NICE TA1056
MolnupiravirOptimised16 Apr 2025
Updated 26 Feb 2026
Current
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
NICE TA1055
RucaparibOptimised16 Apr 2025Current
Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over
NICE TA1054
RuxolitinibRecommended15 Apr 2025Current
Cladribine for treating active relapsing forms of multiple sclerosis
NICE TA1053
CladribineOptimised15 Apr 2025Current
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal)
NICE TA1052
—Terminated (no company submission)2 Apr 2025Current
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over
NICE TA1051
Efanesoctocog alfaOptimised2 Apr 2025Current
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
NICE TA1050
—Not recommended26 Mar 2025Current
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia
NICE TA1049
BlinatumomabOptimised26 Mar 2025Current
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable
NICE TA1048
Lisocabtagene maraleucelOptimised26 Mar 2025Current
Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)
NICE TA1047
AtezolizumabTerminated (no company submission)12 Mar 2025Current
Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma
NICE TA1046
ZolbetuximabNot recommended12 Mar 2025Current
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites
NICE TA1045
—Optimised Not recommended5 Mar 2025
Updated 26 Aug 2026
Current
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over
NICE TA1044
—Optimised (Innovative Medicines Fund)26 Feb 2025Current
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
NICE TA1043
OsimertinibRecommended26 Feb 2025Current
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
NICE TA1042
SelpercatinibOptimised19 Feb 2025Current
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer
NICE TA1041
DurvalumabOptimised19 Feb 2025Current
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy
NICE TA1040
OlaparibRecommended12 Feb 2025Current
Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over
NICE TA1039
SelpercatinibRecommended12 Feb 2025Current
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over
NICE TA1038
SelpercatinibOptimised12 Feb 2025Current
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer
NICE TA1037
PembrolizumabRecommended5 Feb 2025Current
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment
NICE TA1036
ElacestrantOptimised5 Feb 2025Current
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease
NICE TA1035
—Recommended23 Jan 2025Current
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours
NICE TA1034
—Recommended22 Jan 2025Current
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over
NICE TA1033
—Not recommended12 Feb 2025Current
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal)
NICE TA1032
NiraparibTerminated (no company submission)22 Jan 2025Current
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over
NICE TA1031
VamoroloneRecommended16 Jan 2025Current
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer
NICE TA1030
DurvalumabRecommended15 Jan 2025Current
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal)
NICE TA1029
—Terminated (no company submission)15 Jan 2025Current
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)
NICE TA1028
BimekizumabTerminated (no company submission)15 Jan 2025Current
Tebentafusp for treating advanced uveal melanoma
NICE TA1027
TebentafuspRecommended9 Jan 2025Current
Tirzepatide for managing overweight and obesity
NICE TA1026
TirzepatideOptimised23 Dec 2024
Updated 1 Sep 2025
Current
Ublituximab for treating relapsing multiple sclerosis
NICE TA1025
UblituximabOptimised18 Dec 2024Current
Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal)
NICE TA1024
ToripalimabTerminated (no company submission)11 Dec 2024Current
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments
NICE TA1023
ElranatamabOptimised (Cancer Drugs Fund)11 Dec 2024Current
Bevacizumab gamma for treating wet age-related macular degeneration
NICE TA1022
—Recommended4 Dec 2024Current
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
NICE TA1021
CrizotinibOptimised4 Dec 2024Current
Eplontersen for treating hereditary transthyretin-related amyloidosis
NICE TA1020
EplontersenRecommended27 Nov 2024Current
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over
NICE TA1019
CrovalimabRecommended20 Nov 2024Current
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis
NICE TA1018
FedratinibOptimised20 Nov 2024Current
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer
NICE TA1017
PembrolizumabRecommended20 Nov 2024Current
Elafibranor for previously treated primary biliary cholangitis
NICE TA1016
ElafibranorRecommended14 Nov 2024Current
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments
NICE TA1015
TeclistamabOptimised13 Nov 2024Current
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer
NICE TA1014
AlectinibRecommended13 Nov 2024Current
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia
NICE TA1013
QuizartinibRecommended23 Oct 2024Current
Avapritinib for treating advanced systemic mastocytosis
NICE TA1012
AvapritinibRecommended6 Nov 2024Current
Belzutifan for treating tumours associated with von Hippel-Lindau disease
NICE TA1011
BelzutifanRecommended (Cancer Drugs Fund)16 Oct 2024Current
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria
NICE TA1010
DanicopanOptimised23 Oct 2024Current
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
NICE TA1009
—Optimised2 Oct 2024Current
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments
NICE TA1008
—Recommended25 Sep 2024Current
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
NICE TA1007
RucaparibRecommended17 Sep 2024Current
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)
NICE TA1006
—Terminated (no company submission)12 Sep 2024Current
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
NICE TA1005
FutibatinibRecommended11 Sep 2024Current
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion
NICE TA1004
FaricimabRecommended11 Sep 2024Current
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over
NICE TA1003
—Recommended (Innovative Medicines Fund)11 Sep 2024Current
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over
NICE TA1002
—Recommended11 Sep 2024Current
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment
NICE TA1001
ZanubrutinibRecommended4 Sep 2024Current
Iptacopan for treating paroxysmal nocturnal haemoglobinuria
NICE TA1000
IptacopanRecommended4 Sep 2024Current
Vibegron for treating symptoms of overactive bladder syndrome
NICE TA999
VibegronOptimised4 Sep 2024Current
Risankizumab for treating moderately to severely active ulcerative colitis
NICE TA998
RisankizumabOptimised22 Aug 2024Current
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma
NICE TA997
PembrolizumabRecommended29 Aug 2024Current
Linzagolix for treating moderate to severe symptoms of uterine fibroids
NICE TA996
—Optimised14 Aug 2024Current
Relugolix for treating hormone-sensitive prostate cancer
NICE TA995
RelugolixRecommended14 Aug 2024Current
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal)
NICE TA994
EnzalutamideTerminated (no company submission)8 Aug 2024Current
Burosumab for treating X-linked hypophosphataemia in adults
NICE TA993
—Recommended7 Aug 2024Current
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
NICE TA992
Trastuzumab deruxtecanNot recommended29 Jul 2024Current
Abaloparatide for treating osteoporosis after menopause
NICE TA991
—Optimised7 Aug 2024Current
Tenecteplase for treating acute ischaemic stroke
NICE TA990
TenecteplaseRecommended24 Jul 2024Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.